Study of Kidney Cancer Genetics in Ashkenazi Jewish Families
Name of the Trial
Genetic Study of Patients With Inherited Urologic Malignancies (NCI-89-C-0086). See the protocol summary.
Dr. W. Marston Linehan, principal investigator, and Dr. Berton Zbar, associate investigator, of the NCI’s Center for Cancer Research.
Why Is This Trial Important?
Approximately 32,000 people each year in the U.S. are diagnosed with kidney cancer. While a number of risk factors have been associated with kidney cancer, such as smoking, obesity, and high blood pressure, previous studies suggest that genes may also play a strong role in determining who will develop this disease.
In this study, researchers will analyze blood and tissue samples from persons with suspected or confirmed inherited kidney cancer. Researchers are especially interested in enrolling Ashkenazi Jews from families that have at least two members with this disease. Due to their history, Ashkenazi Jews share a similar genetic makeup. Researchers hope this similarity will help them find a new gene associated with kidney cancer.
“This study continues the NCI’s work to discover genes that may contribute to the development of kidney cancer,” said Dr. Zbar. “Subsequently, we hope to develop a diagnostic test that would identify people at greater risk for developing the disease so that preventive measures can be taken or the disease can be treated before it has had a chance to metastasize.”
Who Can Join This Trial?This trial currently seeks to recruit 50-100 Ashkenazi Jewish families with two or more family members affected by kidney cancer.See the full list of eligibility criteria for this trial.
Where Is This Trial Taking Place?
The study is taking place at the National Institutes of Health (NIH) Warren G. Magnuson Clinical Center in Bethesda, Md.
For more information, contact Shyla Hale, study coordinator, at 1-800-949-6704 or email@example.com. The call is toll-free and completely confidential.